Brief Reports
Copyright ©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Jun 21, 2005; 11(23): 3623-3627
Published online Jun 21, 2005. doi: 10.3748/wjg.v11.i23.3623
Table 2 Influence of DNMT3B SNP on the risk of development and lymphatic metastases of GCA.
GroupDNMT3B genotype T/Tn (%) C/TaOR (95%CI)P
Overall
Control279 (94.9)15 (5.1)
GCA205 (96.7)7 (3.3)0.66 (0.26-1.67)0.38
Nonsmoker
Control130 (96.3)5 (3.7)
GCA78 (95.1)4 (4.9)1.43 (0.37-5.56)0.61
Smoker
Control98 (95.1)5 (4.9)
GCA111 (97.4)3 (2.6)0.61 (0.14-2.69)0.51
Family history of UGIC in
GCA patients82 (96.5)3 (3.5)0.40(0.05-3.14)0.38
Positive97 (96.0)4 (4.0)0.94 (0.35-2.50)0.91
Negative
GCA with LM data
LM- (n = 62)58 (93.5)4 (6.5)
LM+(n = 69)67 (97.1)2 (2.9)0.45 (0.08-2.63)0.38